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Original Research Article 
Prevalence of Hepatitis G virus among patients with chronic liver disease and 
healthy individuals, Sana'a city-Yemen. 
 
Abstract 
Hepatitis G virus (HGV) is a newly discovered and enveloped RNA positive-
stranded flavivirus-like particle, which has not yet been proven to have major 
negative effects on liver. Therefore, it is important to estimate the prevalence and 
risk factors of hepatitis G virus infection in Yemeni viral hepatitis patients and 
general population to design standard prevention and treatment plans. Screening 
HGV antibodies among  60 chronic HBV and 144 chronic HCV patients 
comparing with it's prevalence in 218 healthy controls were carried out. Serum 
samples were collected and tested for human HGV IgG by commercially available 
ELISA technique. Demographic data such as gender, age, and risk factors of 
contracting HGV virus were recorded in predesigned questionnaire.  The crude 
prevalence rate of HGV was 2.8%, female specific rate was 0% and male specific 
rate was 3.5%. The prevalence of HGV among HBV patients was 0%; HCV was 
1.4% while in healthy individuals it was 4.6%. When age groups considered, the 
prevalence of HGV among age groups 20-29 years and 30-39 years was 3.5%, 
while in older age groups the rate of HGV was 0%.  There was a trend towards 
increased levels of HGV infection with the second and third decades of life 
(3.5%). There was no significant association between HGV infection and risk 
factors of hepatitis viruses. It can be concluded from this study that HGV virus is 
circulating in the risk groups and in the community in general Yemen, and there is 
a possibility that this virus may at some time become epidemic if preventive 
measures are not applied. The risk of community among healthy people more than 
in risk groups as HBV and HCV patients. Additionally HGV increases with young 
male adults. 
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Introduction  
   From 1995 to 1996, two independent laboratories in the USA isolated a new 
enveloped RNA virus similar to flaviviruses. The first laboratory named it GB virus 
C/GBV-C and the second as hepatitis G virus (HGV)
 1
. HGV is a virus in the 
flaviviridae family and known to be infectious for human, but it has not been 
established to cause human disease with certainly 
2
. However, there is a suspicious 
link between HGV infection and acute or fulminant hepatitis, chronic hepatitis and 
hepatic fibrosis 
3, 4
. High prevalence is observed among subjects with risk of 
parenteral exposure including those with exposure to blood and blood products 
5
. 
Approximately, 2% of healthy United States blood donors had viremia with HGV and 
up to 13% of blood donors had antibodies against E2 protein, indicating a possible 
prior infection 
6
. Sexual contact and vertical transmission could be another route of 
HGV transmission 
6
.  Furthermore, HCV and HBV infected patients have evidence of 
higher rate of HGV infection 
7, 8
. However, none of the studies indicated that HGV 
infection can cause any liver enzyme elevation or hepatic failure certainly, but co-
infection with other hepatitis viremia can increase morbidity and mortality rates 
9
. 
HGV prevalence rate among healthy and the role of this agent in acute and chronic 
liver disease in Yemen is absent or at least poorly understood, so this study was 
carried out as one of the first study to detected the prevalence rate of HGV /GBV-C 
  
among HBV and HCV infected patients comparing with healthy controls, and risk 
factors of transmission HGV /GBV-C and the co-infection with HBV and HCV in 
Yemen. 
Subjects and Methods 
        This study was carried out during a period of nine months, starting in March 2015 
and ending in November 2015.  A total of 422individuals were included; 218 healthy 
controls, 60 of chronic HBV patients and 144 chronic HCV patients attended to the main 
general hospitals in the Sana'a city.  Serum samples were collected and tested for 
human HGV IgG by commercially available ELISA technique (Roche). A full history 
was taken from each studied individual; and the findings were recorded in a 
predesigned questionnaire. The data collected included name, age at the time of the 
study, sex, marital status, residence, date, clinical and diagnostic data, risk factors and 
laboratory results. 
Statistical Analysis 
To relate possible risk factors for HGV infection, the data were examined in a case-
control study format. For HGV, persons with evidence of previous or current infection 
with HGV (antibodies-positive) were matched up with those who were HGV 
antibodies negative.  
Ethical Consideration 
Ethical clearance for the study was taken from the Faculty of Medicine and Health 
Sciences Research Review Committee. Informed Consent was taken from the 
volunteers before the collecting specimens. 
RESULTS 
The crude prevalence rate of HGV was 2.8%, female specific rate was 0% and male 
specific rate was 3.5%. The prevalence of HGV among HBV patients was 0%; HCV 
was 1.4% while in healthy individuals it was 4.6%. When age groups considered, the 
prevalence of HGV among age groups 20-29 years and 30-39 years was 3.5%, while 
in older age groups the rate of HGV was 0%.  Risk Factors to HGV: From the study 
participants 8.7% reported that they had direct contact with hepatitis patients, 3.1% 
had sexual contact with HBV or HCV patients, 8.3% had household with HBV or 
HCV patients, 47.4% had history of dental visit, 68.2 sharing blades and scissors, 
10.2% had blood transfusion, 16.6% had  cupping and 33% had history of surgery 
(table3).  Associated Odds ratio of HGV: There were significant risk factors of 
HGV with males in which the rate was 3.5%, while in female the rate was 0% 
(p<0.001). In respect of age groups, there was no significant risk factors of HGV 
(table 2). In respect of risk factors, there were no significant risk factors of HGV with 
usual risk factors of hepatitis G virus (table 4).  
Discussion 
   The present study represents the first investigation of HGV infection in patients 
with chronic hepatitis B and HCV living in Sana'a city, Yemen. HGV was detected by 
ELISA in 12 (2.8%) of all patients and healthy controls. The rate of HGV was 0% for 
HBV-infected patients, 1.4% for HCV-infected patients and 4.6% for healthy 
controls.  The values related to co-infection of HGV with HCV and HBV in our study 
were lower from that reported by Amini et al, Ghanbari et al. and Zali et al.  in Iran in 
which the rate of HGV with HBV was varying between 5% and 43% 
10, 11, 12
.  Also, 
Yang et al. in Taiwan showed that co-infections of HGV with HBV and HCV were 
18% and 55%, respectively 
13
, Tanaka et al, 1998 in Japan showed that co-infection of 
HGV with HCV was 10.9% 
14
, in Thailand Barusruk and Urwijitaroon et al, 2006 
showed that co-infection with HCV was 10% 
15
, and in Egypt HGV with HCV was 
64.9% 
16
. Additionally, in some studies, co-infection of HGV with HCV and HBV 
  
was reported with lower values than that of Iran and Taiwan. Alvarado-Mora et al. in 
Colombia reported that 5.06% of HBsAg-positive samples were also HGV-positive, 
while 3.2% of HCV positive cases were HGV-positive 
17
, which in the case of HBV 
samples is higher to our findings but much slightly higher than the co-infection rate of 
HGV and HCV in the present study (1.4%).  There is a large variation and difference 
in the prevalence of HGV infection in different geographical regions. This difference 
may be due to the volume of the population involved in the study, methodology used 
to detect HGV infection, demographic and clinical features of patients, and different 
patterns of transmission of virus around the world (blood and blood components, 
sexual routes, intravenous injection, etc 
18
. 
  However, the present study represents the first investigation of HGV infection in 
healthy controls in Yemen. The HGV prevalence rate in the present study among 
healthy controls was 4.6%, higher than that in hepatitis patients (0% with HBV, and 
1.4% with HCV). Our rate among healthy individuals is lower than that reported from 
Africa 
19
 (33%), US 
20
 (1 3%), and the 33% of China 
21
. Thus HGV infection 
prevalence in Yemeni healthy people (4.8%) could be regarded as a low level.  Since 
in the present study 218 healthy individuals were enrolled and selected randomly, the 
calculated prevalence data for hepatitis G in them are reliable. However, in general, 
all results published showed that hepatitis G infection was uncommon in healthy 
individuals, and this was also confirmed by our study. 
   The specific female prevalence of HGV was 0% among both patients and healthy 
control females, while male prevalence was 3.5 %. Our result was different to the sex 
distribution of HGV /GBV-C infection in western countries where equal distribution 
is the feature in all reports 
22, 23
. In addition; the present study showed that there was 
trend toward increased levels of HGV /GBV-C infection with the second, and  the 
third decades of life where the rates were 3.5% , with OR=1.4, and  7.1% with 
OR=2.95 respectively. This similar to findings in prospective study of 2796 
hemodialysis patients seen in Germany 
24
 which reported that higher prevalence of 
HGV /GBV-C were in the 3
rd
 decades of life among hemodialysis patients. The 
increasing of prevalence rate with increasing age in our study could indicate an 
accumulation risk of infection over time. 
There was no significant association between HGV /GBV-C infection and history of 
all parenteral transmission routes (table 4), and this opposite to the findings by Fogeda 
et al. 
25
 and Basaras et al. 
26
 that prior factors were risk factors for HGV /GBV-C in 
Spain and Germany.  
Conclusion 
It can be concluded from this study that HGV virus is circulating in the risk groups 
and in the community in Sana'a city, and there is a possibility that this virus may at 
some time become epidemic if preventive measures are not applied. The risk of 
exposure to HGV increases with advancing age, and no significant risks of 
contracting HGV through parenteral transmission. 
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Table 1: The prevalence rate and association odds ratio of HGV among HBV, 
HCV patients and healthy controls  
Characters 
 
Anti-E2 positive 
(HGV positive) 
OR CI χ2 P 
No % 
HBV chronic patients 
n=60 0 0 0 0.0-2.6 2.1 0.15 
HCV chronic patients 
n= 144 
2 1.4 0.36 0.05-1.8 1.8 0.17 
Healthy controls 
n=218 
10 4.6 4.8 1.04-32.5 5 0.02 
Total n=422 12  
2.8 
    
OR   Odds ratio = RR (relative risk) =› 1at risk 
CI    Confidence intervals 
χ2     Chi-square =≥ 3.84 (significant) 
p      Probability value =‹ 0.05 (significant) 
 
 
  
Table 2: The prevalence rate and associated odds ratio of HGV among different 
sexes and age groups among total patients and controls 
Sex & age groups 
Anti-E2 positive 
(HGV positive) 
OR CI χ2 P 
No % 
Sex  
Male n=342 
12 3.5 undefined 422 <0.001 
Female n= 80 0 0 0.0 0.0-1.8 2.9 0.08 
Age groups   
 
20-29  years 
N=170 
 
6 
3.5 1.44 0.4-5.14 0.39 0.53 
30 – 39 years 
N= 114 
4 3.5 1.4 0.34-5.12 0.25 0.61 
40 – 49 years 
N= 60 
0 0 0.0 0.0-2.6 2.1 0.15 
50 – 59 years 
N= 50 
0 0 0.0 0.0-3.2 1.7 0.19 
>59 years n=28 2 7.1 2.95 0.0-15.5 2.01 0.15 
OR   Odds ratio = RR (relative risk) =› 1at risk 
CI    Confidence intervals 
χ2     Chi-square =≥ 3.84 (significant) 
p      Probability value =‹ 0.05 (significant) 
Table 3.  The risk factors to HGV in tested hepatitis patients and healthy 
controls at Sana'a city  
 
Risk factors Yes No 
No % No % 
Direct contact with hepatitis patients  37 8.7 385 63 
Sexual contact: with HBV, HCV   13 3.1 409 87 
Household with HBV, HCV   35 8.3 387 91.7 
Abroad travel 42 10 380 90 
History dental visit 200 47.4 222 52.6 
History sharing blades, scissors  288 68.2 134 31.8 
Blood transfusion 43 10.2 279 89.8 
History parental exposure 3 0.71 419 99.29 
History of cupping 70 16.6 352 83.4 
History of surgery 97 33 325 77 
     
 
 
 
 
  
Table 4: The potential risk factors of HGV infection in total patients and 
controls groups.  
 
 Risk factors  
 Anti-E2 
positive 
(HGV positive) OR CI χ2 P 
No % 
Direct contact with 
hepatitis patients n=37 
 
0 
0 0.0 0.0-4.5 1.19 0.27 
Sexual contact: with 
HBV, HCV  (n=13) 
0 0 0.0 0.0-14.7 0.39 0.53 
Household with 
HBV, HCV  (n=35) 
0 0 0.0 0.0-4.8 1.12 0.29 
Abroad travel: (n=42) 0 0 0.0 0.0-3.93 1.37 0.24 
History dental visit: 
(n=200) 
4 2 0.55 0.14-2 0.98 0.32 
History repeated use of 
needles: (n=0) 
0 0 undefined 
History sharing blades, 
scissors (n=288) 
6 2.1 0.4 0.12-1.5 2.3 0.12 
Blood hemodialysis 
 (n=0) 
0 0 undefined 
Blood transfusion  
(n=43) 
1 2.3 0.77 0.1-5.9 0.06 0.8 
History parental 
exposure (n=3) 
0 0 0.0 0.0-86 0.09 0.76 
History patient receive 
a tattoo: (n=0) 
0 0 undefined 
History of cupping: 
 (n=70) 
2 2.9 0.98 0.2-4.3 0.00 0.97 
History of surgery: 
 (n=97) 
2 2.1 0.6 0.1-3.19 0.32 0.56 
OR   Odds ratio = RR (relative risk) =› 1at risk 
CI    Confidence intervals 
χ2     Chi-square =≥ 3.84 (significant) 
p      Probability value =‹ 0.05 (significant) 
 
 
 
